Seattle Genetics releases more promising brentuximab data; Oxigene trial demonstrates spike in thyroid cancer survival rate;

 @FierceBiotech: Boehringer stops female libido drug program. Article | Follow @FierceBiotech

 @JohnCFierce: Happy to see Mario Vargas Llosa win the Nobel this week. Can't remember the last time they gave it to someone whose work I know. |  Follow @JohnCFierce

> Seattle Genetics has released another promising set of data for brentuximab, or SGN-35. The developer said that 86 percent of patients with advanced systemic anaplastic large cell lymphoma responded to treatment in a Phase II study. Just last month Seattle Genetics released positive data from a study on advanced Hodgkin's disease. Story

> Oxigene reports that a new trial of Zybrestat demonstrated a one-month boost in survival time for thyroid cancer patients. And researchers said that close to half of the patients in the drug/chemo arm were alive at six months, compared with 37 percent of the patients receiving only chemotherapy. Report

> NanoInk has closed a $65 million financing led by Lurie Investments. NanoInk specializes in nanometer-scale manufacturing and apps development for the life sciences and other industries. NanoInk release

> Auxilium has launched a late-stage study of Xiaflex as a treatment for abnormal curvature of the penis. The drug is already approved as a treatment for Dupuytren's contracture, which causes fingers to curl in. Story

And Finally... Researchers at The University of Western Ontario have discovered there is a causal link between enhanced visual abilities and a reorganization of the part of the brain that handles auditory input in congenitally deaf cats. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.